Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Ranibizumab
Related studies linked through entity extraction aliases.
Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration
- Status
- COMPLETED
- Phase
- PHASE2
Lucentis (Ranibizumab) for Eales' Disease
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial
- Status
- COMPLETED
- Phase
- PHASE1
Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
- Status
- COMPLETED
- Phase
- PHASE1
SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
- Status
- COMPLETED
- Phase
- PHASE3
Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
- Status
- COMPLETED
- Phase
- PHASE1